## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($121.65)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Is Abbott Laboratories Still Attractively Priced After Recent Medical Device Momentum In 2025?**
- Source: Simply Wall Street | 20251217T224303 | Neutral | Relevance: 100%
- Abbott Laboratories (NYSE: ABT) has seen recent stock momentum, with a 15.3% return over the last year. While a Discounted Cash Flow (DCF) analysis suggests it might be overvalued by 72.7% at its current share price of $126, its Price-to-Earnings (PE) ratio of 15.8x is significantly below the industry average, indicating it could be undervalued based on earnings. The article also introduces "Narratives" as a way for investors to create dynamic valuations based on different future outlooks for the company.

**2. Nilsine Partners LLC Cuts Stake in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251217T111949 | Somewhat-Bullish | Relevance: 100%
- Nilsine Partners LLC reduced its stake in Abbott Laboratories (NYSE:ABT) by 46.5% during the third quarter, selling 11,583 shares and retaining 13,316 shares valued at $1.784 million. This comes as Abbott reported Q3 EPS of $1.30, in line with estimates, and revenue of $11.37 billion, slightly below expectations, while also raising its quarterly dividend to $0.63 per share. Several analysts maintain positive ratings on ABT, with an average price target of $147.00.

**3. Insight Wealth Strategies LLC Invests $4.91 Million in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251216T134407 | Bullish | Relevance: 100%
- Insight Wealth Strategies LLC initiated a new position in Abbott Laboratories (NYSE:ABT) during the third quarter, acquiring 36,673 shares valued at approximately $4.91 million. Abbott Laboratories recently reported Q3 EPS of $1.30 and revenue of $11.37 billion, and has raised its quarterly dividend to $0.63, reflecting a "Moderate Buy" consensus rating among analysts with a price target of $147.00. Institutional investors collectively own about 75% of the shares in the company.

**4. 17,830 Shares in Abbott Laboratories $ABT Bought by B. Riley Wealth Advisors Inc.**
- Source: MarketBeat | 20251215T082440 | Bullish | Relevance: 100%
- B. Riley Wealth Advisors Inc. acquired 17,830 shares of Abbott Laboratories (NYSE:ABT) in the second quarter, valued at approximately $2.43 million, increasing institutional ownership to about 75.18%. Abbott reported strong Q3 earnings, meeting analyst estimates, and increased its quarterly dividend while maintaining a "Moderate Buy" consensus rating from analysts.

**5. Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025**
- Source: ts2.tech | 20251215T001729 | Neutral | Relevance: 100%
- Abbott Laboratories (ABT) faces a busy Monday with several key headlines, including a dividend hike, regulatory attention on FreeStyle Libre sensors, and a major acquisition of Exact Sciences. Investors will also be tracking baby formula litigation and the expansion of Abbott's Lingo product. These factors will influence ABT's stock performance as the market opens, against a backdrop of generally positive analyst sentiment but near-term uncertainties.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 4 ($0.12M) |
| Sells | 2 ($0.39M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Momentum building: MRS_10 improving +6.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 22.3x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $220.5B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 22.3 |
| Current P/E | 24.6 |
| YoY Growth | 10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -1.6% to 4.5% (+6.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 78th percentile. MRS_5 at 2.3% confirms short-term momentum alignment. Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 51. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.49% (CS: 79) | Strong |
| RSI_14 | 51.3 | Neutral |
| MACD Histogram | 0.30 | Bullish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.996x | Below |
| vs SMA200 | 0.972x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $126.69
- **Stop Loss:** $121.65 (4.0% risk)
- **Target:** $131.73 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 214
- **Position Value:** $27,111.66
- **Portfolio %:** 27.11%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-07 01:40 | MRS_10*